FIELD: medicine.
SUBSTANCE: group of inventions relates to ophthalmology, namely to a method of improving visual function, a method of treating and/or normalizing dryness symptoms and a method of treating dry keratoconjunctivitis. Disclosed is a method for improving visual function in a patient suffering dry eye syndrome (dry keratoconjunctivitis), wherein the patient is characterized by that he has: total ocular surface disease index (OSDI) equal to or greater than 55; at least one eye with a fluorescein staining score of 3 (NEI scale); and at least one eye with a total fluorescein staining score of at least 11 (on the NEI scale) at the initial level, wherein the visual function is improved in the patient, and wherein the method involves a step of administering composition containing 0.1 wt./v.% of cyclosporine dissolved in 1-(perfluorobutyl)pentane, and up to 1.0 wt./wt.% of ethanol into the patient's eye, wherein said composition is introduced into the eye twice a day in a dose of one drop in a volume of approximately 8–12 mcl per eye. Method of treating and/or normalizing dryness symptoms associated with keratoconjunctivitis (dry eye syndrome) in a patient in need thereof, involving the local administration of an ophthalmic composition containing 0.1 wt./v.% of cyclosporine, dissolved in 1-(perfluorobutyl)pentane, and up to 1.0 wt./wt.% of ethanol, wherein said composition is administered into the eye twice a day in a dose of one drop of 8–10 mcl per eye, wherein the patient has said indicators; wherein the method is effective for reducing the total score of corneal staining with fluorescein in at least one eye by at least 3 points after 4 weeks of treatment. Method of treating dry keratoconjunctivitis (dry eye syndrome) involving a stage of local administration of an ophthalmic composition containing 0.1 wt./v.% of cyclosporine, dissolved in 1-(perfluorobutyl)pentane, and up to 1.0 wt./wt.% of ethanol; wherein said composition is administered into the eye twice a day in a dose of one drop in a volume of about 8–10 mcl per eye, wherein the patient has said values; wherein said methods are effective for reducing the total score of corneal staining with fluorescein in at least one eye by at least 3 points.
EFFECT: use of the group of inventions provides the treatment of dry eye syndrome, in which the following parameters are simultaneously observed in the patient: higher average change in total OSDI relative to baseline in patients with OSDI ≥ 55 compared to the general population of patients in the study, improved visual function in a patient is characterized by a decrease in the total score of corneal staining with fluorescein (according to the NEI scale) by 3 or more units, at least one eye with a fluorescein staining score of 3 (on the NEI scale), a total fluorescein staining score for at least one eye of at least 11 on the NEI scale at the initial level.
23 cl, 11 dwg, 1 ex
Title | Year | Author | Number |
---|---|---|---|
OPHTHALMIC COMPOSITIONS FOR THE TREATMENT OF OCULAR SURFACE DAMAGE AND DRY EYE SYMPTOMS | 2019 |
|
RU2806212C2 |
COMPOSITION FOR EFFECTIVE LIPID DELIVERY TO HUMAN TEAR FILM USING SALT-SENSITIVE EMULSION SYSTEM | 2012 |
|
RU2772357C2 |
METHOD OF TREATING DRY EYE SYNDROME | 2015 |
|
RU2581495C1 |
METHOD FOR CHOOSING PATHOGENETICALLY CAUSED THERAPEUTIC APPROACH TO VIRAL OCULAR DISEASES | 2012 |
|
RU2494741C1 |
DRY EYE TREATMENT COMPOSITIONS | 2012 |
|
RU2651046C2 |
ARTIFICIAL TEARS COMPRISING SODIUM HYALURONATE AND CARBOXYMETHYLCELLULOSE | 2014 |
|
RU2687275C2 |
GEL-LIKE ARTIFICIAL TEARS WITH ANTISEPTIC AND REPARATIVE ACTION | 2018 |
|
RU2679319C1 |
OPHTHALMIC COMPOSITION CONTAINING CYCLOSPORINE AND TREHALOSE | 2015 |
|
RU2700927C2 |
ESTERS FOR TREATMENT OF OPHTHALMOLOGICAL INFLAMMATORY DISEASES | 2012 |
|
RU2640506C9 |
METHOD FOR TREATMENT OF HEAVY FORMS OF DRY KERATOCONJUNCTIVITIS | 2016 |
|
RU2621553C1 |
Authors
Dates
2024-10-17—Published
2019-10-11—Filed